Trial Profile
Phase II trial of trasutuzumab plus docetaxel for previous trastuzumab treated unresectable or recurrent HER2 positive gastric cancer (T-CORE1203)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 07 Jul 2020 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Jun 2013 New trial record